Analysts' ratings for argenx ARGX over the last quarter vary from bullish to bearish, as provided by 15 analysts.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 5 | 10 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 2 | 0 | 0 | 0 |
| 3M Ago | 4 | 8 | 0 | 0 | 0 |
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $547.0, along with a high estimate of $640.00 and a low estimate of $504.00. This upward trend is evident, with the current average reflecting a 5.82% increase from the previous average price target of $516.93.
Investigating Analyst Ratings: An Elaborate Study
The standing of argenx among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Yatin Suneja | Guggenheim | Maintains | Buy | $585.00 | $585.00 |
| James Gordon | JP Morgan | Raises | Overweight | $640.00 | $500.00 |
| Joel Beatty | Baird | Raises | Outperform | $515.00 | $490.00 |
| Yatin Suneja | Guggenheim | Raises | Buy | $585.00 | $545.00 |
| Leland Gershell | Oppenheimer | Raises | Outperform | $560.00 | $546.00 |
| David Nierengarten | Wedbush | Raises | Outperform | $560.00 | $519.00 |
| Derek Archila | Wells Fargo | Raises | Overweight | $547.00 | $543.00 |
| Douglas Tsao | HC Wainwright & Co. | Raises | Buy | $533.00 | $504.00 |
| Leland Gershell | Oppenheimer | Announces | Outperform | $546.00 | - |
| Joon Lee | Truist Securities | Raises | Buy | $540.00 | $480.00 |
| David Nierengarten | Wedbush | Maintains | Outperform | $519.00 | $519.00 |
| Douglas Tsao | HC Wainwright & Co. | Raises | Buy | $504.00 | $490.00 |
| David Nierengarten | Wedbush | Maintains | Outperform | $519.00 | $519.00 |
| Gavin Clark-Gartner | Evercore ISI Group | Raises | Outperform | $533.00 | $478.00 |
| David Nierengarten | Wedbush | Maintains | Outperform | $519.00 | $519.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to argenx. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of argenx compared to the broader market.
- Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of argenx's stock. This examination reveals shifts in analysts' expectations over time.
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of argenx's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on argenx analyst ratings.
Discovering argenx: A Closer Look
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.
Unraveling the Financial Story of argenx
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Over the 3 months period, argenx showcased positive performance, achieving a revenue growth rate of 76.54% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 6.09%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 0.68%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): argenx's ROA stands out, surpassing industry averages. With an impressive ROA of 0.61%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: argenx's debt-to-equity ratio is below the industry average. With a ratio of 0.01, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
The Significance of Analyst Ratings Explained
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
